These findings support the rationale for targeting mTORC1 in HER2/neu-positive cancers to improve therapeutic outcomes; however, direct downregulation of SREBP1-dependent pathways to block the effects of HER2/neu activation or to overcome therapy resistance needs further investigation. Here, ERBB2 is linked to cancer.